Onose G, Haras M, Anghelescu A, Mureşanu D, Giuglea C, Daia Chendreanu C
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
J Med Life. 2010 Jul-Sep;3(3):262-74.
The last two decades have come up with some important progresses in the genetic, immune, histochemical and bio (nano)-technological domains, that have provided new insight into cellular/molecular mechanisms, occurring in the central nervous system (CNS)--including in spinal cord-injuries.
In previous works, emerging from our theoretical and practical endeavors in the field, we have thoroughly described the principal intimate propensity and the pathophysiological processes--representing intrinsic limitations for self-recovery after SCI, and, at the same time, subtle targets for neuroprotection/recovery--and reviewed the main related worldwide-published reports. The aim of this paper is to emphasize the connections between such main aspects and some feasible integrative solutions, including the ones for clinical practice.
Consequently, we stress upon some therapeutic suggestions regarding this subject matter by systematizing the most up to date and efficient ones--obviously, within major limits, according to the very low capacities of CNS/ spinal cord (SC) to post-injury self preserve and recover. Moreover, we also talk about accessible drugs, respectively those being already in clinical use (but at present, mainly used to treat other conditions, including the neurological ones) and hence, with relatively well known, determined effects and/or respectively, restrictions.
The recent advances in the knowledge on the basic components of the afore mentioned CNS/ SC propensity for self destroying and inefficient endogenous repair mechanisms in the actual new context, will hopefully be, from now on, more effectively correlated with revolutionary--mostly still experimental--treatments, especially by using stem cells within tissue engineering, including, if needed, more advanced/courageous approaches, based on somatic cell nuclear transfer (SCNT).
This paper contains the scientific motivated highlighting of some already available drugs, "neuroprotective" (and not only) properties too, which enable practitioners with (although not yet capable to cure--but anyway) more efficient therapeutic means, to approach the extremely difficult and still painfully disappointing domain, of spinal cord injury (SCI).
在过去二十年里，遗传、免疫、组织化学和生物（纳米）技术领域取得了一些重要进展，这些进展为中枢神经系统（CNS）（包括脊髓损伤）中发生的细胞/分子机制提供了新的见解。
在之前基于我们在该领域的理论和实践努力而开展的工作中，我们已经详尽描述了主要的内在倾向和病理生理过程——这些过程是脊髓损伤后自我恢复的内在限制因素，同时也是神经保护/恢复的微妙靶点——并回顾了全球发表的主要相关报告。本文的目的是强调这些主要方面与一些可行的综合解决方案之间的联系，包括临床实践中的解决方案。
因此，我们通过梳理最新且有效的治疗建议——显然，鉴于中枢神经系统/脊髓（SC）损伤后自我修复和恢复能力极低，这些建议存在很大局限性——来强调关于这一主题的一些治疗建议。此外，我们还讨论了可获取的药物，分别是那些已在临床使用（但目前主要用于治疗其他病症，包括神经方面的病症）、因而具有相对已知且明确的效果和/或限制的药物。
在当前新背景下，关于上述中枢神经系统/脊髓自我破坏倾向和低效内源性修复机制基本组成部分的知识最新进展，有望从现在起与革命性的——大多仍处于实验阶段的——治疗方法更有效地关联起来，特别是通过在组织工程中使用干细胞，包括在必要时采用基于体细胞核移植（SCNT）的更先进/大胆的方法。
本文科学地强调了一些已有药物的“神经保护”（不仅如此）特性，这些特性使从业者能够（尽管还无法治愈——但无论如何）采用更有效的治疗手段，来应对脊髓损伤（SCI）这一极其困难且仍然令人痛苦失望的领域。
